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Abstract
A 60 year old lady was referred to the Princess Alexandra Hospital (Brisbane, Queensland, Australia) tertiary Otolar-
yngology, Head and Neck Unit from a peripheral hospital for investigation and management of a tumour at the
base of the tongue. Biopsy of the tumour revealed it to be an epithelial-myoepithelial carcinoma of the base of
the tongue. This is an extremely rare tumour in this location with only 2 other case reports in the world literature:
the patients were treated with chemo-radiotherapy and surgery respectively. Our patient was made aware of the
world literature and was able to make a fully informed decision on her choice of treatment modality and was trea-
ted with radiotherapy. Increasingly journals are limiting publication of case reports to “world firsts” only. We present
a case where such a policy would have denied patient choice and possibly led to detrimental treatment.
We review the world literature of tongue base epithelial-myoepithelial carcinoma of the tongue.
Introduction
Epithelial-myoepithelial carcinoma is an rare tumour
occurring in the salivary glands, (most commonly in the
parotid gland), with a reported incidence of between
0.2% [1] and 1% [2,3] of salivary duct tumours. It is a
hybrid tumour, composed of two different tumour enti-
ties, each of which conforms to a defined tumour cate-
gory [4,5] and based upon the Salivary Gland Register at
the University of Hamburg. Specimens collected
between 1965 and 1994 showed that only 0.1% of sali-
vary gland tumours were hybrid tumours [5]. Other
examples of hybrid tumours include mucoepidermoid
carcinoma, basaloid-squamous carcinoma, adeno-squa-
mous carcinoma, sarcomatoid carcinoma and carcinoma
in pleomorphic adenoma with differentiation as squa-
mous cell carcinoma as well as adenocarcinoma [5].
Case Report
A 60 year old lady was referred to the Princess Alexan-
dra Hospital Head and Neck Clinic in July 2009 follow-
ing a biopsy taken from a suspected tumour at the base
of the tongue (BOT). The patient was referred to our
unit for ongoing investigation and management. She
had noted a one year history of dysphagia and difficulty
i nm o v i n gh e rt o n g u e .O u rp a t i e n ta l s on o t e da nu n i n -
tended a 25 kg weight loss over the past year and had
had a PEG feeding tube inserted in the interim before
being referred to our department. The patient confirmed
that she was an ex-smoker with a 30 pack year history
but denied alcohol consumption.
On examination there was limited movement of her
tongue with significant tethering (Figure 1 and 2). A
large mass was palpable predominantly on the right side
of the base of the tongue and there were no masses
palpable in the neck.
An MRI taken shows an extensive BOT tumour across
the midline which extends to involve the right faucial
tonsil. The tumour has an intermediate T2 signal with
foci of bright T2 fluid within (Figure 3). The intermedi-
ate T1 signal tumour shows irregular enhancement fol-
lowing Gadolinium (Figure 4, 5). The tumour appears
exophytic. The tumour extended inferiorly to the level
of the epiglottis which it displaced posteriorly. The ver-
tical length of the tumour was 3.7 cm. Small (approx 1
cm) lymphadenopathy was noted bilaterally in level 2
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involved with tumour in view of the size, morphological
appearance and clinical nature of the disease. The
appearances of the BOT tumour are not typical for the
more common SCC in this location with the irregular
bright T2 signal. However an unusual SCC appearance
is still be more likely than a minor salivary gland rare
tumour based a review of the literature.
A panendoscopy was performed which revealed a 4
cm submucosal lesion with a firm, posterior tongue
(Figure 6). The mass extended over the midline, into the
inferior half of the tonsil and into the vallecula but the
glossal epiglottis was clear of tumour. The mass was not
fixed to the mandible. Histological examination of the
biopsy samples demonstrated epithelial-myoepithelial
carcinoma of the tongue base. The morphology and the
pattern of immunoreacitivity are typical for Epithelial-
Myoepithelial carcinoma (Table 1 and Figures 7, 8, 9
and 10). The results of the panendoscopy and the biopsy
were discussed with the patient and a thorough litera-
ture review enabled the multidisciplinary Head and
Figure 1 Extent of limited tongue protrusion due to tumour
invasion of tongue muscles.
Figure 2 Close up of the tongue, with the patient protruding
tongue maximally.
Figure 3 Axial T2 Fat saturated MRI representing mass invading right base of tongue extending across the midline involving the right
faucial tonsil. Mass shows immediate T2 signal enhancement with bright focus within.
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Page 2 of 7Figure 4 Sagittal T1MRI, sagittal view, mass located at the base of the tongue.
Figure 5 Axial intermediate T1 Fat saturated MRI, post gadolinium on lesion on right base of tongue. Lesion has irregular enhancement
following gadolinium
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options.
Planning by the Radiation Oncology team was under-
taken with a view to a 60 Gy treatment over 30 fractions
with a 2 cm margin around the primary tumour. Her
treatment was well tolerated although she did require
daily hyoscine injections to dry up excessive secretions.
She has had a complete clinical response and will be fol-
lowed with a new MRI in 6 months.
Literature Review
2 cases have been reported in the literature of epithelial-
myoepithelial carcinoma in the base of the tongue [1,6]
with contrasting modes of treatment (Table 2).
These two cases were both published as “world firsts”
and whilst sharing a common histology of tumours in
an identical location (base of tongue), were where mana-
ged in different ways. This allowed our team to present
the patient with options for management of her rare
tumour.
Discussion
There are three major salivary glands–parotid, subman-
dibular, and sublingual–as well as innumerable minor
salivary glands distributed throughout the mucosa of the
oral cavity and nasopharynx. All these glands are subject
to inflammation or to the development of neoplasms
[7]. These glands give rise of over 30 histologically dis-
tinct tumours [7].
The tumours in Table 3 represent only around 2% of
human neoplasms and occur predominantly in the paro-
tid gland (60-80%), followed by the submandibular gland
(10%) and then the minor salivary glands (including the
sublingual gland) [7]. Interestingly, the parotids have the
lowest level of malignancy (15-30%), with the subman-
dibular gland (40%) and the minor salivary gland having
a 50% malignancy rate, whilst the rate of malignancy in
the sublingual gland is 70-90% [7].
Epithelial-myoepithelial carcinomas are defined, histo-
logically, by tubular or ductal structures lined by both
basal myoepithelial cells and luminal epithelial cells
similar to normal intercalated salivary gland ducts.
Whilst neoplasms are monoclonal and, as such, com-
prise one cell type, there are uncommon tumours at all
sites which show divergent differentiation. In some case,
as for this tumour, this can be explained by the com-
mon precursor cells for both of the cell types repre-
sented in tis particular tumour.
Immunohistochemistry for expression of different cell
proteins is essential in identifying the two cell types
demonstrated in this tumour. The outer basal or myoe-
pithelial cell layer expresses p63 (figure 8), low molecular
weight cytokeratins (CK5/6) and variably expresses other
cytokeratin subclasses because these cells unique in
expressing both epithelial and smooth muscle characteris-
tics reflecting their normal function of lining ducts AND
being capable of contraction to aid salivary fluid flow. The
inner luminal layer is typical of all epithelial cells in
expressing cytokeratin but not smooth muscle proteins.
This tumour displayed the typical and characteristic
features of Epithelial-Myoepithelial Carcinoma with an
inner luminal epithelial layer (cytokeratin positive only
Figures 7 &9) and an outer myoepithelial cell layer
(cytokeratin positive Figure 9) and co-expression of
smooth muscle proteins (Figures 8 &10).
Table 1 Histology results for biopsy
IMMUNOHISTOCHEMISTRY RESULT
p63 Positive in basal cells (nuclear)
CK5/6 Positive in luminal cell (cytoplasmic);
positive in basal cell (Golgi)
HMWCK (CK34) Positive in luminal cell (cytoplasmic);
positive in basal cell (Golgi)
SMA Positive in basal cells
AE1/AE3 Positive in luminal cells
Figure 6 Intraoperative views of the mass at the base of the tongue.
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commonly occur in the parotid gland, but as with all
salivary gland tumours, may arise anywhere in the naso-
oro-pharynx in relation to minor salivary glands. By
definition, an epithelial-myoepithelial carcinoma is a
hybrid tumour, which is a tumour consisting of two dis-
tinctly different entities, each of which conforms to an
exactly defined tumour category [5].
Epithelial-myoepithelial are, low grade malignant
tumours although some tumours do exhibit more rapid
growth and high grade behaviour. Histologically the
high grade tumours show evidence of dedifferentiation
which is not seen otherwise. Tumour behaviour can,
therefore to some extent, be predicted by histologic fea-
tures. In this case, the prediction would low grade
malignancy.
During a study of 954 consecutive salivary gland
tumours, Fonseca et al [8] found 22 epithelial-myoe-
pithelial carcinomas (2.3%). In all these cases, the
tumours were excised with the associated salivary gland.
Follow up of these patients indicated a recurrence rate
of 41% with a 5 year survival rate of 87.5% and a 10
year survival rate of 67.5%. This rate of recurrence was
similar to what was observed by Corio et al (39%) [9].
A review of the literature has revealed only two pre-
vious instances at the base of tongue [6,10] which were
treated with chemo-radiation and surgery respectively
without recurrence over a year later. Surgery and chemo-
radiation are the two treatment modalities reported in
the literature to have been used in base of tongue
tumours and it is extremely helpful in a tertiary referral
centre to have instant access to the only published
experience with this particular tumour in this location.
It is important for very rare cases such as this to be
reported particularly in respect of behaviour and treat-
ment so as to build a database for these tumours. The
current trend in journals not to publish case reports not
Figure 7 AE1/AE3 Immunohistochemistry stain of epithelial-
myoepithelial carcinoma.
Figure 8 p63 Immunohistochemistry stain of epithelial-
myoepithelial carcinoma in the base of the tongue.
Figure 9 CK5/6 Immunohistochemistry stain of epithelial-
myoepithelial carcinoma, biopsy taken from mass at base of
tongue.
Figure 10 SMA stain, Immunohistochemistry stain from mass
at the base of tongue in a 60 year old female patient.
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publishing ladder but, as in our patient’s case, could
have severely limits evidence based options. Journals not
publishing case report include CA: A Cancer Journal for
Clinicians (Impact factor 2007 69.26) and the Journal of
the American Medical Association (JAMA - Impact fac-
tor 2007 25.5), both highly respected journals with high
ranking ISI impact factors.
Whilst the authors do not advocate that every journal
should practice publishing case reports that have been
published multiple times in the past, we would argue
that limiting the world literature to “world firsts” will be
to the detriment of our patients.
Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
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